CoChat

Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND METHODS: To examine the clinical course of human immunodeficiency virus (HIV) infection in injection-drug users, we conducted a prospective study of a cohort of patients in a methadone-treatment program in New York City from July 1985 through December 1990. The patients underwent standardized evaluations at base line and semiannually thereafter and received on-site primary medical care. Rates of progression to the acquired immunodeficiency syndrome (AIDS) and major outcomes before the development of AIDS were examined by univariate analyses; the risk of AIDS was also assessed by product-limit survival analysis and proportional-hazards regression. RESULTS: Of 318 HIV-seropositive patients who did not yet have AIDS (171 men and 147 women), 90 were black, 179 were Hispanic, and 49 were white; the median age was 33 years. Over a median of 3.0 years of follow-up, 55 (17 percent) received a diagnosis of AIDS (incidence per 100 person-years, 5.8). Major outcomes before the development of AIDS included oral candidiasis (incidence per 100 person-years, 11.2), pyogenic bacterial infections including pneumonia and sepsis (8.0), pulmonary tuberculosis (1.2), multiple constitutional symptoms (13.6), and herpes zoster (1.3). There were 41 deaths from AIDS, and 13 seropositive patients without AIDS (4.1 percent) died of bacterial infections, as compared with only 1 of 411 seronegative patients studied (P < 0.001). The incidence of AIDS was 62 percent lower among those who took zidovudine than among those who did not (P = 0.02). In the multivariate analysis, progression to AIDS was best predicted by low numbers and percentages of CD4+ lymphocytes, nonuse of zidovudine, and the presence of oral candidiasis, bacterial infections, or tuberculosis. There was no consistent relation between progression to disease and the continued use of injection drugs. CONCLUSIONS: HIV-infected injection-drug users have progression to AIDS at rates comparable to those of other HIV-infected groups, but they have substantial pre-AIDS morbidity and mortality, particularly from bacterial infections, which also appear to predict disease progression.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199212103272401

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Research works printed but not linked: 15

  1. 1989, MMWR Morb Mortal Wkly Rep, 38, 165
  2. 1991, Wkly Epidemiol Rec, 66, 33
  3. Muñoz, 1992, J Acquir Immune Defic Syndr, 5, 694
  4. Des Jarlais, 1987, AIDS, 1, 105
  5. Casabona, 1990, J Acquir Immune Defic Syndr, 3, 272
  6. 1989, MMWR Morb Mortal Wkly Rep, 38, 1
  7. Gates JR, Collado E, Budner NS, Schoenbaum EE. Retaining participation in a prospective study of HIV among intravenous drug users (IVDUs) in New York City. In: Abstracts of the Seventh International Conference on AIDS, Florence, Italy, June 16–21, 1991. Vol. 2. Rome: Istituto Superiore di Sanità, 1991:377.
  8. 1986, MMWR Morb Mortal Wkly Rep, 35, 334
  9. 1987, MMWR Morb Mortal Wkly Rep, 36, 1S
  10. 1991, MMWR Morb Mortal Wkly Rep, 40, 891
  11. 1990, Wkly Epidemiol Rec, 65, 221
  12. 1991, MMWR Morb Mortal Wkly Rep, 40, 1
  13. Selik, 1990, J Acquir Immune Defic Syndr, 3, 73
  14. Ragni, 1990, J Acquir Immune Defic Syndr, 3, 708
  15. Rosenberg, 1991, J Acquir Immune Defic Syndr, 4, 392

Cited by

See all 282

Metadata

Authors
Selwyn, P. A., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E. E., Klein, R. S., Davenny, K., & Friedland, G. H.
Affiliations
Albert Einstein College of Medicine (US)
Venue
New England Journal of Medicine
Published
1992-12-10
Volume
327
Issue
24
Pages
1697-1703
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2337820820
Cited by
282
References
54
Citations by year
2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 7 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 7
FWCI
15.62
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01da004347-15)
  • U.S. Public Health Service (U64CCU200714)
  • National Institute on Drug Abuse (DAO4347-05)
Topics
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
HIV infection, people who inject drugs, AIDS progression, methadone maintenance treatment, zidovudine, CD4 count, oral candidiasis, bacterial infection, tuberculosis, AIDS mortality, risk factors for progression
MeSH terms
Acquired Immunodeficiency Syndrome, Adult, Bacterial Infections, Candidiasis, Oral, Female, Follow-Up Studies, Humans, Leukocyte Count, Male, New York City, Prospective Studies, Zidovudine, CD4-Positive T-Lymphocytes, HIV Infections, Substance Abuse, Intravenous, Multivariate Analysis, Proportional Hazards Models, AIDS-Related Opportunistic Infections, Racial Groups

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. https://app.cochat.ai/papers/10.1056/nejm199212103272401
The paper
Selwyn, P. A., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E. E., Klein, R. S., Davenny, K., & Friedland, G. H. (1992). Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal of Medicine. https://doi.org/10.1056/nejm199212103272401

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.